Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 400

Similar articles for PubMed (Select 23402035)

1.

Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics.

Mehan MR, Ostroff R, Wilcox SK, Steele F, Schneider D, Jarvis TC, Baird GS, Gold L, Janjic N.

Adv Exp Med Biol. 2013;735:283-300. Review.

PMID:
23402035
2.

Aptamer-based multiplexed proteomic technology for biomarker discovery.

Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D.

PLoS One. 2010 Dec 7;5(12):e15004. doi: 10.1371/journal.pone.0015004.

3.

High-content affinity-based proteomics: unlocking protein biomarker discovery.

Brody EN, Gold L, Lawn RM, Walker JJ, Zichi D.

Expert Rev Mol Diagn. 2010 Nov;10(8):1013-22. doi: 10.1586/erm.10.89. Review.

PMID:
21080818
4.

Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery.

Berger AB, Vitorino PM, Bogyo M.

Am J Pharmacogenomics. 2004;4(6):371-81. Review.

PMID:
15651898
5.

Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents.

Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, Janjic N.

Mol Ther Nucleic Acids. 2014 Oct 7;3:e201. doi: 10.1038/mtna.2014.49. Review.

6.

Low molecular weight protein enrichment on mesoporous silica thin films for biomarker discovery.

Fan J, Gallagher JW, Wu HJ, Landry MG, Sakamoto J, Ferrari M, Hu Y.

J Vis Exp. 2012 Apr 17;(62). pii: 3876. doi: 10.3791/3876.

7.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
8.

Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.

Cohen Freue GV, Meredith A, Smith D, Bergman A, Sasaki M, Lam KK, Hollander Z, Opushneva N, Takhar M, Lin D, Wilson-McManus J, Balshaw R, Keown PA, Borchers CH, McManus B, Ng RT, McMaster WR; Biomarkers in Transplantation and the NCE CECR Prevention of Organ Failure Centre of Excellence Teams.

PLoS Comput Biol. 2013 Apr;9(4):e1002963. doi: 10.1371/journal.pcbi.1002963. Epub 2013 Apr 4.

9.

Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine.

Thiele T, Steil L, Völker U, Greinacher A.

BioDrugs. 2007;21(3):179-93. Review.

PMID:
17516713
10.

Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.

Gupta S, Hirota M, Waugh SM, Murakami I, Suzuki T, Muraguchi M, Shibamori M, Ishikawa Y, Jarvis TC, Carter JD, Zhang C, Gawande B, Vrkljan M, Janjic N, Schneider DJ.

J Biol Chem. 2014 Mar 21;289(12):8706-19. doi: 10.1074/jbc.M113.532580. Epub 2014 Jan 12.

11.

Urinary proteomics--a tool for biomarker discovery.

Pejcic M, Stojnev S, Stefanovic V.

Ren Fail. 2010 Jan;32(2):259-68. doi: 10.3109/08860221003599759. Review.

PMID:
20199189
12.

Interpretation of large-scale quantitative shotgun proteomic profiles for biomarker discovery.

Isserlin R, Emili A.

Curr Opin Mol Ther. 2008 Jun;10(3):231-42. Review.

PMID:
18535930
13.

Advances in human proteomics at high scale with the SOMAscan proteomics platform.

Gold L, Walker JJ, Wilcox SK, Williams S.

N Biotechnol. 2012 Jun 15;29(5):543-9. doi: 10.1016/j.nbt.2011.11.016. Epub 2011 Dec 7. Review.

PMID:
22155539
14.

Approaching clinical proteomics: current state and future fields of application in fluid proteomics.

Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, Kellner R, Kubicek M, Lottspeich F, Maser E, Mewes HW, Meyer HE, Müllner S, Mutter W, Neumaier M, Nollau P, Nothwang HG, Ponten F, Radbruch A, Reinert K, Rothe G, Stockinger H, Tarnok A, Taussig MJ, Thiel A, Thiery J, Ueffing M, Valet G, Vandekerckhove J, Verhuven W, Wagener C, Wagner O, Schmitz G.

Clin Chem Lab Med. 2009;47(6):724-44. doi: 10.1515/CCLM.2009.167. Review.

PMID:
19527139
15.

Systematic selection of modified aptamer pairs for diagnostic sandwich assays.

Ochsner UA, Green LS, Gold L, Janjic N.

Biotechniques. 2014 Mar 1;56(3):125-8, 130, 132-3. doi: 10.2144/000114134. eCollection 2014.

16.

Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.

Calvo KR, Liotta LA, Petricoin EF.

Biosci Rep. 2005 Feb-Apr;25(1-2):107-25. Review.

17.

Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents.

Nery AA, Wrenger C, Ulrich H.

J Sep Sci. 2009 May;32(10):1523-30. doi: 10.1002/jssc.200800695. Review.

PMID:
19472283
18.

Strategies for plasma proteomic profiling of cancers.

Omenn GS.

Proteomics. 2006 Oct;6(20):5662-73. Review.

PMID:
16991194
19.

Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.

Matta A, Ralhan R, DeSouza LV, Siu KW.

Mass Spectrom Rev. 2010 Nov-Dec;29(6):945-61. doi: 10.1002/mas.20296. Review.

PMID:
20945361
20.

High-throughput proteomics using antibody microarrays.

Wingren C, Borrebaeck CA.

Expert Rev Proteomics. 2004 Oct;1(3):355-64. Review.

PMID:
15966831
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk